SG11202006506TA - Methods for treating farber disease - Google Patents

Methods for treating farber disease

Info

Publication number
SG11202006506TA
SG11202006506TA SG11202006506TA SG11202006506TA SG11202006506TA SG 11202006506T A SG11202006506T A SG 11202006506TA SG 11202006506T A SG11202006506T A SG 11202006506TA SG 11202006506T A SG11202006506T A SG 11202006506TA SG 11202006506T A SG11202006506T A SG 11202006506TA
Authority
SG
Singapore
Prior art keywords
methods
farber disease
treating farber
treating
disease
Prior art date
Application number
SG11202006506TA
Other languages
English (en)
Inventor
Eric Gaukel
Brante Sampey
Original Assignee
Enzyvant Therapeutics Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enzyvant Therapeutics Gmbh filed Critical Enzyvant Therapeutics Gmbh
Publication of SG11202006506TA publication Critical patent/SG11202006506TA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/47Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/50Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/24Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405Glucanases
    • C12N9/2408Glucanases acting on alpha -1,4-glucosidic bonds
    • C12N9/2411Amylases
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y302/00Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01045Glucosylceramidase (3.2.1.45), i.e. beta-glucocerebrosidase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG11202006506TA 2018-02-02 2019-01-31 Methods for treating farber disease SG11202006506TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862625763P 2018-02-02 2018-02-02
PCT/IB2019/000077 WO2019150192A1 (en) 2018-02-02 2019-01-31 Methods for treating farber disease

Publications (1)

Publication Number Publication Date
SG11202006506TA true SG11202006506TA (en) 2020-08-28

Family

ID=65951809

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202006506TA SG11202006506TA (en) 2018-02-02 2019-01-31 Methods for treating farber disease

Country Status (15)

Country Link
US (2) US20190240298A1 (es)
EP (1) EP3746115A1 (es)
JP (2) JP2021512853A (es)
KR (1) KR20200118011A (es)
CN (1) CN112703010A (es)
AU (1) AU2019214519A1 (es)
BR (1) BR112020015003A2 (es)
CA (1) CA3088225A1 (es)
CL (1) CL2020001856A1 (es)
IL (1) IL276284A (es)
MX (1) MX2020007501A (es)
PH (1) PH12020551146A1 (es)
RU (1) RU2020118032A (es)
SG (1) SG11202006506TA (es)
WO (1) WO2019150192A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3568154B1 (en) * 2017-01-13 2023-07-12 Icahn School of Medicine at Mount Sinai Compositions and methods for treating farber disease
US20220088158A1 (en) * 2019-01-23 2022-03-24 Aceragen, Inc. Method of ameliorating a pro-inflammatory immunophenotype in farber disease subjects by repeated administration of a recombinant human acid ceramidase
WO2021050064A1 (en) * 2019-09-11 2021-03-18 Icahn School Of Medicine At Mount Sinai Anc80 encoding sphingolipid-metabolizing proteins for mitigating disease-induced tissue damage

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012177997A1 (en) * 2011-06-22 2012-12-27 The General Hospital Corporation Treatment of proteinopathies
CN112126634A (zh) * 2013-01-09 2020-12-25 夏尔人类遗传性治疗公司 含用于纯化芳基硫酸酯酶a的方法
RU2768003C2 (ru) * 2013-03-08 2022-03-22 Джензим Корпорейшн Интегрированное непрерывное производство терапевтических белковых лекарственных веществ
HUE046113T2 (hu) 2013-03-14 2020-02-28 Icahn School Med Mount Sinai Terápiás sav ceramidáz készítmények és azok elõállítási és felhasználási eljárásai
EP3568154B1 (en) 2017-01-13 2023-07-12 Icahn School of Medicine at Mount Sinai Compositions and methods for treating farber disease
WO2019060837A1 (en) * 2017-09-25 2019-03-28 Enzyvant Farber Gmbh PROCESS FOR PRODUCING RECOMBINANT HUMAN ACID CERAMIDASE

Also Published As

Publication number Publication date
CA3088225A1 (en) 2019-08-08
JP2023113809A (ja) 2023-08-16
AU2019214519A1 (en) 2020-06-18
IL276284A (en) 2020-09-30
BR112020015003A2 (pt) 2020-12-29
CL2020001856A1 (es) 2020-12-04
KR20200118011A (ko) 2020-10-14
US20190240298A1 (en) 2019-08-08
PH12020551146A1 (en) 2021-06-28
WO2019150192A1 (en) 2019-08-08
EP3746115A1 (en) 2020-12-09
JP2021512853A (ja) 2021-05-20
CN112703010A (zh) 2021-04-23
RU2020118032A (ru) 2022-03-02
US20230123505A1 (en) 2023-04-20
MX2020007501A (es) 2020-10-16

Similar Documents

Publication Publication Date Title
IL281633A (en) Methods for treating Huntington's disease
IL277190A (en) Methods of treating HPV-related diseases
IL275265A (en) Macrocyclic compounds for the treatment of disease
IL277333A (en) Methods for treating eye diseases
IL278247B (en) mct4 inhibitors to treat the disease
HK1253238A1 (zh) 用於治療疾病的gls1抑制劑
SI3393468T1 (sl) Postopki za zdravljenje bolezni imunske pomanjkljivosti
IL288958A (en) Exosomes for the treatment of diseases
IL276284A (en) Methods for treating Ferber's disease
IL263161B (en) New compounds for the treatment of parasitic diseases
IL255506A (en) A method for treating a neurological disease
GB201721287D0 (en) Treatment for inflammatory disease
IL269743A (en) Methods and preparations for the treatment of disease related to the retina with CCR-3 inhibitor inventions
SG11202102878TA (en) Treatment methods
IL281839A (en) Treatment methods
EP3568154A4 (en) COMPOSITIONS AND METHODS OF TREATMENT FOR COLOR SYNDROME
IL270552A (en) Valclospoin preparation for the treatment of proteinaceous kidney disease
EP3773693A4 (en) METHODS OF TREATMENT OF AUTOIMMUNE DISEASES
HK1256099A1 (zh) 用於治療移植物抗宿主病的組合物和方法
IL275091A (en) Methods for treating Gaucher's disease
ZA202001927B (en) Method for treating tnf alpha-related diseases
EP3796978A4 (en) METHOD OF TREATING CARDIOVASCULAR DISEASE
EP3577224A4 (en) NEW TREATMENT FOR NEAT1-ASSOCIATED DISEASES
IL246608A0 (en) Preparations and methods for treating heart disease
EP4058063A4 (en) METHODS OF TREATMENT OF DISEASES